Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Post by retiredcopon Jan 18, 2021 1:16pm
324 Views
Post# 32320787

Impact on PMN

Impact on PMNSo we have two companies that have publically shown that their treatment for AD is working.to some extent.  Yes the data is not overwhelming , the drugs are not perfect, but so far this has been the most positive news in at least 10 years .  Here is a link to a reputable grooup and in this article a very important point is made ... this is what impacts PMN's future .... pretty clear. about what other companies need to hear inorder to push them to proceed in the same direction.. 

https://www.alzforum.org/news/research-news/phase-2-donanemab-curbs-cognitive-decline-early-alzheimers

 
It’s a good day for the field,” said Eric Siemers of Siemers Integration, LLC, who worked at Lilly when the trial began but has since retired. “We now have one more monoclonal antibody signaling in the right direction.”

Cynthia Lemere of Brigham and Women’s Hospital in Boston welcomed the news. “Lilly’s Phase 2 positive findings lend further support to the amyloid hypothesis and validate Aβ as a therapeutic target for early-stage AD,” she wrote (full comment below).
 


<< Previous
Bullboard Posts
Next >>